Sorrento Therapeutics Announces Discovery of a Potential Non-Dopaminergic Approach to Controlling Parkinson’s Motor Symptoms With Resiniferatoxin (RTX) Intrathecal Administration
April 10, 2019 09:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, April 10, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announces positive and better than initially hoped for top line results in a discovery study...
Sorrento Therapeutics Announces Interim Results In Osteoarthritis Knee Pain Phase 1b Trial of Resiniferatoxin With Positive Therapeutic Signal and Absence of Dose Limiting Toxicities; Pivotal Trials Targeted to Start Later 2019
January 22, 2019 07:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced that the phase 1b study of its non-opioid, afferent nerve ablating drug candidate...
1st Patient Treated for Osteoarthritis Knee Pain in Sorrento Resiniferatoxin Phase 1B Trial Meets Both Safety and Efficacy Expectations
August 13, 2018 04:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that the first enrolled patient in the phase 1b study of its non-opioid, afferent nerve...